(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 11.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Taysha Gene Therapies's revenue in 2025 is $8,098,000.On average, 15 Wall Street analysts forecast TSHA's revenue for 2025 to be $2,174,448,028, with the lowest TSHA revenue forecast at $1,149,557,645, and the highest TSHA revenue forecast at $4,296,519,439. On average, 13 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,250,491,753, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $4,296,519,439.
In 2027, TSHA is forecast to generate $4,105,563,019 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $14,522,235,703.